Profile data is unavailable for this security.
About the company
Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
- Revenue in DKK (TTM)205.01m
- Net income in DKK-44.52m
- Incorporated2008
- Employees219.00
- LocationGubra A/SHoersholm Kongevej 11 BHOERSHOLM 2970DenmarkDNK
- Websitehttps://www.gubra.dk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Philogen SpA | 172.51m | -45.95m | 4.36bn | 160.00 | -- | 8.90 | -- | 25.29 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
| Abivax SA | 0.00 | -1.32bn | 4.80bn | 62.00 | -- | 5.05 | -- | -- | -3.20 | -3.20 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -77.89 | -65.49 | -107.73 | -97.67 | -- | -- | -- | -- | -- | -110.67 | 0.4334 | -- | -- | -- | -111.52 | -- | -19.06 | -- |
| Basilea Pharmaceutica AG Allschwil | 1.17bn | -5.12m | 4.87bn | 156.00 | -- | 33.97 | 539.75 | 4.16 | -0.2814 | -0.2814 | 11.54 | 1.38 | 0.7118 | 1.22 | 4.40 | 1,013,755.00 | -0.3114 | -1.86 | -0.4156 | -2.99 | 76.57 | 83.45 | -0.4375 | -2.99 | 3.27 | -1.38 | 0.8508 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Kuros Biosciences AG | 412.94m | -69.84m | 5.95bn | 80.00 | -- | 12.37 | -- | 14.41 | -0.2295 | -0.2295 | 1.73 | 1.64 | 0.6755 | 1.95 | 7.89 | 656,775.00 | -11.42 | -13.47 | -13.53 | -14.84 | 79.13 | 78.73 | -16.91 | -81.48 | 2.17 | -- | 0.0847 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Formycon AG | 453.46m | 476.56m | 6.39bn | 239.00 | 12.13 | 1.49 | 12.98 | 14.08 | 4.00 | 4.00 | 3.64 | 32.64 | 0.0654 | 34.46 | 1.55 | 255,462.20 | 6.87 | 5.87 | 7.37 | 6.33 | 12.46 | 28.54 | 105.09 | 39.76 | 2.06 | -- | 0.0185 | 0.00 | 82.83 | 12.47 | 110.59 | 60.58 | 81.87 | -- |
| Evotec SE | 5.88bn | -1.27bn | 7.95bn | 5.02k | -- | 1.05 | -- | 1.35 | -0.9634 | -0.9634 | 4.45 | 5.70 | 0.3667 | 18.94 | 4.10 | 155,787.40 | -7.94 | -0.0064 | -9.88 | -0.0076 | 15.98 | 24.51 | -21.65 | -0.0178 | 1.73 | -1.70 | 0.3189 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| BioArctic AB | 196.59m | -57.98m | 8.16bn | 96.00 | -- | 16.03 | 263.61 | 41.51 | -0.9972 | -0.9972 | 3.39 | 10.52 | 0.2699 | -- | -- | 3,401,659.00 | -7.96 | 2.24 | -8.90 | 2.56 | 88.22 | 86.52 | -29.49 | 9.76 | -- | -- | 0.0604 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Gubra A/S | 205.01m | -44.52m | 8.27bn | 219.00 | -- | 17.19 | -- | 40.35 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Genus plc | 5.95bn | 70.32m | 10.85bn | 3.48k | 155.62 | 2.22 | 24.68 | 1.82 | 0.1186 | 0.1186 | 10.14 | 8.30 | 0.6569 | -- | 5.37 | -- | 0.2357 | 3.30 | 0.2742 | 3.87 | -- | -- | 0.3589 | 4.98 | 1.42 | 279.50 | 0.3487 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| AddLife AB | 6.56bn | 77.49m | 12.40bn | 2.32k | 165.55 | 3.80 | 18.01 | 1.89 | 0.9683 | 0.9683 | 81.96 | 42.19 | 0.7438 | 3.47 | 5.30 | 4,340,287.00 | 0.8937 | 5.31 | 1.37 | 8.83 | 37.24 | 36.89 | 1.20 | 5.79 | 0.4779 | 1.67 | 0.5113 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
Data as of Sep 23 2024. Currency figures normalised to Gubra A/S's reporting currency: Danish Krone DKK
9.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 1.25m | 7.67% |
| Schroder Investment Management Ltd.as of 31 Dec 2023 | 100.00k | 0.61% |
| Deka Investment GmbHas of 31 Oct 2023 | 86.11k | 0.53% |
| Danske Bank A/S (Investment Management)as of 31 May 2024 | 47.21k | 0.29% |
| Schroder Investment Management (Europe) SA (Finland)as of 30 Apr 2024 | 43.00k | 0.26% |
| Medical Strategy GmbHas of 30 Apr 2024 | 13.00k | 0.08% |
| Exchange Traded Concepts LLCas of 03 Jul 2024 | 9.85k | 0.06% |
| E. �hman J :or Fonder ABas of 31 May 2024 | 9.73k | 0.06% |
| Neos Investment Management LLCas of 03 Jul 2024 | 6.96k | 0.04% |
| J.O. Hambro Capital Management Ltd.as of 30 Jun 2024 | 6.28k | 0.04% |
More ▼
Data from 31 Mar 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
